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A commentary on
The evolving role of monoclonal
antibodies in colorectal cancer: early
presumptions and impact on clinical trial
development
by Eng, C. (2010). Oncologist 15, 73–84.
One of the most successfully approach
in the treatment of metastatic colorec-
tal cancer (mCRC) is the inhibition of
the Epidermal Growth Factor Receptor
(EGFR) pathway by antibodies (cetux-
imab and panitumumab). Notably, ran-
domized trials with anti-EGFR antibodies
have shown a significant impact of KRAS
[wild type (wt) vs. mutated (mut)] on
response and prognosis: the presence of
KRAS activating mutations was found to
be associated with reduced biological and
clinical activity for the treatment (response
rate inmut<20% vs. wt>50%). Thus, the
mutational status of KRAS is now a widely
accepted criteria for selection of patients
who would be most likely to respond to
these treatments. In the next future, other
genes involved in the EGFR pathway could
have a role in the prediction of treatment
response (BRAF, PIK3CA, PTEN, etc.) (De
Roock et al., 2011).
Cetuximab is an IgG1 monoclonal
antibody, it binds specifically to the
extracellular domain of EGFR inhibiting
downstream proliferative, anti-apoptotic
and neoangiogenetic signals in kras wt
tumors and it has clinical efficacy in
mCRC (Eng, 2010). However, one of the
accepted anti-tumor mechanism is the
antibody-dependent cell-mediated cyto-
toxicity (ADCC) in which Fc region
of the antibody binds to the FcγRs
(Fragment c Gamma Receptors) expressed
by immune effector cells (Natural Killer
cells, macrophages, etc.) (Kohrt et al.,
2012). However, the scenario is very
complex and the result is not the sim-
ple sum of the above phenomena. Very
recently, it has been demonstrated that
immunologic mechanisms can cooper-
ate (ADCC) but also antagonize with
the inhibition of EGFR/kras signal. In
fact, CD163+ “tumor-promoting” M2
macrophages which can be abundant in
the microenvironment of colorectal car-
cinomas are activated by cetuximab and
in turn they release anti-inflammatory
and tumor-promoting mediators, includ-
ing IL-10 and VEGF (Pander et al., 2011).
Furthermore, both ADCC and cetuximab-
induced macrophage responses can be
more pronounced for FcγRIIIa 158-Val
(high-affinity receptor for Fc) carriers
(Tsuchiya et al., 2007; Pander et al., 2011).
The different abundance and activity of
CD163+M2macrophages in tumor envi-
ronment could explain the contrasting
results reported in literature on the role
of FcγR polymorphisms in mCRC (Zhang
et al., 2007; Bibeau et al., 2009).
Very recently, we have demonstrated
that homozygous carriers of the 158V
allele of the FcγRIIIa show a high
response rate and a significantly improved
prognosis in kras wt mCRC (Calemma
et al., 2012). This was consistent with
the hypothesis that variants of human
IgG-receptors can influence the extent of
ADCC and, thus, response to anti-EGFR
therapy. We made, however, the intrigu-
ing observation that FcγRIIIa polymor-
phisms had a prognostic power also in
the entire series, including patients with
mut kras who did not receive anti-EGFR
therapy (data not shown). To confirm this
observation, we are extending the analysis
of FcγRIIIa polymorphisms to all mCRC
patients referring to our center. Our spec-
ulation is that ADCC could be triggered
by “endogenous” anti-tumor antibodies
binding to “high-affinity” FcγR and might
be capable of mediating a clinically rele-
vant anti-tumor activity. Such antibodies
could be present and work also in mutant
kras mCRC patients. The hypothesis that
“endogenous” rather than “therapeutic”
antibodies might trigger such activity is
fascinating but difficult to demonstrate
and could be responsible of long-term
clinical stabilizations after surgery and/or
radio and/or chemotherapy that we see
in clinical practice. Indirectly, increased
rates of antibody-mediated autoimmune
diseases in 158V carriers suggest that the
polymorphism also plays a relevant role
in the binding of endogenous antibodies
(Matsumoto et al., 2005).
ADCC could be also responsible of
responses to anti-EGFR antibodies seen in
KRAS mut tumors. In fact, Ashraf et al.
(2012) have demonstrated that higher
EGFR expression can predict susceptibility
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to cetuximab-induced immune killing
of CRC cells occurring independently
of KRAS/BRAF/PIK3CA mutations (in
press on Proc. Natl. Acad. Sci. U.S.A.).
Therefore, administration of anti-EGFR
antibodies may be considered in CRC
tumors with higher target expression
and favorable FcγR polymorphisms.
However, the context is very complex and
other factors can influence the response to
anti-tumor antibodies: previous and/or
concomitant therapies, HLA expres-
sion, cytokines production, immune cell
receptors repertoire, etc.
Study of interactions between host and
tumors should be urgently improved to
optimize the prediction of response to
therapeutic antibodies in mCRC.
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